A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
A phase 3 trial of Bempegaldesleukin, Sunitinib, Nivolumab and Cabozantinib in Renal cell carcinoma, run by Nektar Therapeutics, recorded as terminated on the registry.
Overview
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) is a phase 3 interventional study registered as NCT03729245 by Nektar Therapeutics, with 623 participants recorded, started 2018-12-18 and due to reach its primary completion in 2022-01-07. Interventions recorded: bempegaldesleukin, sunitinib, nivolumab, cabozantinib. Conditions recorded: Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma.
Linked to the drug Bempegaldesleukin because the registry names it among its interventions and Renal cell carcinoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialStudy to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence
Shares Nektar Therapeutics, Bempegaldesleukin, Nivolumab and the tag pipeline.
- TrialA Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma
Shares Bempegaldesleukin, Nivolumab and the tag pipeline.
- TrialExtension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
Shares Cabozantinib, Nivolumab and the tag pipeline.
- TrialPembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Shares Sunitinib, Renal cell carcinoma and the tag pipeline.
- TrialA Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Shares Cabozantinib, Renal cell carcinoma and the tag pipeline.
- TrialSavolitinib vs. Sunitinib in MET-driven PRCC.
Shares Sunitinib, Renal cell carcinoma and the tag pipeline.
- TrialPan Tumor Rollover Study
Shares Cabozantinib, Nivolumab and the tag pipeline.
- TrialABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
Shares Nivolumab and the tag pipeline.